Cyproheptadine prevents pergolide-induced valvulopathy in rats: An echocardiographic and histopathological study

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 6, 2009, Pages

  Droogmans, Steven ^a,b   Roosens, Bram ^a,b   Cosyns, Bernard ^a,b   Degaillier, Céline ^a   Hernot, Sophie ^b   Weytjens, Caroline ^a,b   Garbar, Christian ^a   Caveliers, Vicky ^a,b   Pipeleers Marichal, Miriam ^a   Franken, Philippe R ^b   Lahoutte, Tony ^a,b   Schoors, Danny ^a   Van Camp, Guy ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b FACULTY OF MEDICINE AND PHARMACY   (Belgium)

Author keywords

Drugs; Echocardiography; Pathology; Valves

Indexed keywords

CYPROHEPTADINE; PERGOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HISTOPATHOLOGY; MALE; MITRAL VALVE; NONHUMAN; PRIORITY JOURNAL; RAT; VALVULAR HEART DISEASE;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CYPROHEPTADINE; DOPAMINE AGONISTS; DRUG INTERACTIONS; ECHOCARDIOGRAPHY; FIBROSIS; HEART VALVE DISEASES; HEART VALVES; MALE; MYOCYTES, CARDIAC; PERGOLIDE; RATS; RATS, WISTAR; SEROTONIN ANTAGONISTS;

EID: 66949173351     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01177.2008     Document Type: Article

References (34)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588, 1997. (Pubitemid 27360757)
2. Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol 100: 1442-1445, 2007. (Pubitemid 47576024)
3. Droogmans S, Franken PR, Garbar C, Weytjens C, Cosyns B, Lahoutte T, Caveliers V, Pipeleers-Marichal M, Bossuyt A, Schoors D, Van Camp G. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 28: 2156-2162, 2007. (Pubitemid 47517444)
4. Droogmans S, Lauwers R, Cosyns B, Roosens B, Franken PR, Weytjens C, Bossuyt A, Lahoutte T, Schoors D, Van Camp G. Impact of anesthesia on valvular function in normal rats during echocardiography. Ultrasound Med Biol 34: 1564-1572, 2008.
5. Droogmans S, Roosens B, Cosyns B, Hernot S, Weytjens C, Degaillier C, Garbar C, Caveliers V, Pipeleers-Marichal M, Franken PR, Bossuyt A, Lahoutte T, Schoors D, Van Camp G. Echocardiographic and histological assessment of age-related valvular changes in normal rats. Ultrasound Med Biol 35: 558-565, 2009.
6. Elangbam CS, Colman KA, Lightfoot RM, Tyler RD, Wall HG. Endocardial myxomatous change in Harlan Sprague-Dawley rats (Hsd: S-D) and CD-1 mice: its microscopic resemblance to drug-induced valvulopathy in humans. Toxicol Pathol 30: 483-491, 2002. (Pubitemid 34906814)
7. 2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60: 253-262, 2008.
8. 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy-a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Exp Toxicol Pathol 58: 89-99, 2006.
9. Fischel T, Hermesh H, Aizenberg D, Zemishlany Z, Munitz H, Benjamini Y, Weizman A. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 21: 612-615, 2001. (Pubitemid 33116663)
10. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57: 75-81, 2000.
11. Ghosh MN, Parvathy S. The effect of cyproheptadine on water and food intake and on body weight in the fasted adult and weanling rats. Br J Pharmacol 48: 328P-329P, 1973.
12. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005. (Pubitemid 40470647)
13. Hauso O, Gustafsson BI, Loennechen JP, Stunes AK, Nordrum I, Waldum HL. Long-term serotonin effects in the rat are prevented by terguride. Regul Pept 143: 39-46, 2007. (Pubitemid 47212520)
14. 2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 110: 969-974, 2004.
15. 2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513: 225-228, 2005.
16. McDonald PC, Wilson JE, Gao M, McNeill S, Spinelli JJ, Williams OD, Harji S, Kenyon J, McManus BM. Quantitative analysis of human heart valves: does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 11: 251-262, 2002. (Pubitemid 35292241)
17. McDonald PC, Wilson JE, McNeill S, Gao M, Spinelli JJ, Rosenberg F, Wiebe H, McManus BM. The challenge of defining normality for human mitral and aortic valves: geometrical and compositional analysis. Cardiovasc Pathol 11: 193-209, 2002. (Pubitemid 34828271)
18. Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67: 33-36, 1991.
19. 2B receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension 52: 301-307, 2008.
20. O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4: 1005-1014, 2005.
21. Rasmussen VG, Poulsen SH, Dupont E, Ostergaard K, Safikhany G, Egeblad H. Ergotamine-derived dopamine agonists and left ventricular function in Parkinson patients: systolic and diastolic function studied by conventional echocardiography, tissue Doppler imaging, and two-dimensional speckle tracking. Eur J Echocardiogr 9: 803-808, 2008.
22. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117: 50-52, 1992.
23. Reffelmann T, Kloner RA. Transthoracic echocardiography in rats. Evalution of commonly used indices of left ventricular dimensions, contractile performance, and hypertrophy in a genetic model of hypertrophic heart failure (SHHF-Mcc-facp-Rats) compared with Wistar rats during aging. Basic Res Cardiol 98: 275-284, 2003. (Pubitemid 37107654)
24. Roth BL. Drugs and valvular heart disease. N Engl J Med 356: 6-9, 2007.
25. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841, 2000.
26. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29-38, 2007. (Pubitemid 46041751)
27. Schott HC 2nd. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet Clin North Am Equine Pract 18: 237-270, 2002.
28. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63: 1223-1229, 2003. (Pubitemid 36627216)
29. Setola V, Roth BL. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on "fen-phen". Expert Opin Drug Metab Toxicol 1: 377-387, 2005.
30. Stein AB, Tiwari S, Thomas P, Hunt G, Levent C, Stoddard MF, Tang XL, Bolli R, Dawn B. Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic Res Cardiol 102: 28-41, 2007. (Pubitemid 44932769)
31. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363: 1179-1183, 2004. (Pubitemid 38481842)
32. Weytjens C, Cosyns B, D'Hooge J, Gallez C, Droogmans S, Lahoute T, Franken P, Van Camp G. Doppler myocardial imaging in adult male rats: reference values and reproducibility of velocity and deformation parameters. Eur J Echocardiogr 7: 411-417, 2006. (Pubitemid 44645064)
33. Young R, Khorana N, Bondareva T, Glennon RA. Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA). Pharmacol Biochem Behav 82: 404-410, 2005. (Pubitemid 41727953)
34. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356: 39-46, 2007. (Pubitemid 46041752)